Log in
Enquire now
‌

US Patent 10590206 Inert format

Patent 10590206 was granted and assigned to Genmab A/S on March, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
‌
Genmab A/S
Current Assignee
‌
Genmab A/S
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10590206
Date of Patent
March 17, 2020
Patent Application Number
14760157
Date Filed
January 9, 2014
Patent Citations Received
‌
US Patent 11981744 Chimeric polypeptide assembly and methods of making and using the same
0
‌
US Patent 11912781 Humanized complement 5A receptor 1 antibodies and methods of use thereof
0
‌
US Patent 11970544 Antibodies
0
‌
US Patent 11485796 Inert format
‌
US Patent 11535679 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
‌
US Patent 11548952 Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
‌
US Patent 11008399 Antibodies
‌
US Patent 11608383 Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
0
...
Patent Primary Examiner
‌
Meera Natarajan
Patent abstract

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10590206 Inert format

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.